Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Janssen shares data on 6-month schizophrenia shot at ECNP

By Brian Buntz | October 4, 2021

JanssenAt the European College of Neuropsychopharmacology (ECNP), Janssen presented data on the Phase 3 trial for the recently approved schizophrenia treatment Invega Hafyera, paliperidone palmitate 6-month (PP6M).

“We hope that this continues to change the paradigm in treating schizophrenia with long-acting injectables,” said Dean Najarian, associate field director, neuroscience medical affairs at Janssen. “Non-adherence is a major contributor of relapses and associated hospitalizations, and certainly costly to the healthcare systems as well as social dynamics.”

The prospect of a six-month schizophrenia injection can “offer patients and caregivers the potential for a life less defined by their schizophrenia medication,” Najarian said.

Invega Hafyera is the only twice-yearly, long-acting injectable.

Janssen, a subsidiary of Johnson & Johnson (NYSE:JNJ), announced the FDA approval of the formulation on Sept. 1. Approvals in other countries are pending.

FDA approval was based on data from a 12-month, randomized, double-blind, non-inferiority phase 3 global study with 702 patients ages 18 to 70. The mean age in the study was 40.8.

In terms of the phase 3 study design, acutely-ill patients were excluded.

Patients that met the inclusion criteria were “relatively stable patients who were either on an oral antipsychotic had a reason to switch to a long-acting injectable with their investigator,” Najarian said. “Or they were already adequately treated on the one-month or the three-month formulation of paliperidone palmitate.”

The study also included some prior recipients of Invega Sustena, the monthly formulation of paliperidone palmitate, who went through a transition phase to longer-acting formulations of the drug.

The study had a 2:1 randomization with twice as many patients randomized to the six-month versus the three-month formulation in a double-blind fashion.

“Everyone got an injection every three months,” Najarian said. “But the six-month group got an injection with an alternating placebo injection to keep the blind.”

No new safety signals emerged. A total of 92.5% of the Invega Hafyera group remained relapse-free at the end of the study versus 95% of the Invega Trinza group.

Najarian noted that partial adherence to oral medication therapy remains a consistent theme in the schizophrenia treatment landscape. “It’s an inherent problem and, in fact, between 50% to 80% of schizophrenia patients are partially or non-adherent to the oral medications.”

“On average, patients are on four different oral treatments before actually being kind of exposed to the notion of being on a long-acting injectable,” he added. “And at that point, the average patient is about 38 years old.”

Most schizophrenia patients get a diagnosis in their early 20s, often leading to a considerable phase of cycling through various oral medications.

The National Council for Mental Wellbeing and the American Psychiatric Association recently updated their schizophrenia treatment guidance with expanded recommendation of long-acting injectables for appropriate adults with schizophrenia.

Because they are administered in a healthcare facility or pharmacy, “long-acting injectables offer transparency to medication adherence,” Najarian said. “So, if patients miss their appointment, they get a call. It’s a patient-centric approach. It’s shared decisionmaking.”


Filed Under: Psychiatric/psychotropic drugs
Tagged With: Invega Hafyera, Invega Sustenna, Janssen, schizophrenia
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

psilocybin
Psilocybin holds therapeutic promise — but tapping its potential could be a challenge
Compass Pathways
Psilocybin therapy shows promise for treating anorexia and depression in small studies
Sage and Biogen
Sage Therapeutics and Biogen formally pursue FDA approval for zuranolone for depression
Psilocybin
Psilocybin lit up the brains of people with severe depression in small study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50